ADCT - ADC Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

500.7M

Cash

234.3M

Avg Qtr Burn

-36.85M

Short % of Float

4.74%

Insider Ownership

21.06%

Institutional Own.

42.01%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Follicular lymphoma, Mantle cell lymphoma, Diffuse large B cell lymphoma	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Camidanlumab Tesirine (CD25) Details Solid tumor/s, Cancer, Hodgkin Lymphoma	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Diffuse large B cell lymphoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Cancer, Blood cancer, Marginal zone lymphoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Cancer, Blood cancer, Diffuse large B cell lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZYNLONTA + Rituximab Details Blood cancer, Follicular lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mipasetamab Uzoptirine (ADCT-601) (AXL) Details Cancer, Solid tumor/s	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Non-Hodgkin lymphoma, Cancer, Blood cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADCT-602 (CD22) Details Acute lymphoblastic leukemia	Phase 1a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Cancer, Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADCT-901 (targeting KAAG1) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.